Literature DB >> 3391418

Plasma level of estradiol in patients with ovarian malignant tumors.

C G Mählck1, T Bäckström, O Kjellgren.   

Abstract

Plasma concentration of estradiol has been investigated in women with epithelial ovarian carcinoma. Forty-nine postmenopausal and/or oophorectomized women with no other malignant or endocrine disease were included in the study. All FIGO stages and the histological types IC, IIC, IIIC, and V were represented. Tumor volumes were evaluated once a month using bimanual recto-vaginal palpation under full anesthesia. Blood samples were drawn for estradiol radioimmunoassay at monthly intervals during 3 months. Plasma levels were compared with a control group of postmenopausal women with no internal disease or medication. The results show a significantly higher concentration in patients with large tumor volume compared to postmenopausal controls and a positive relationship between tumor volume, stage, and plasma estradiol level. Histological type seems to be of less importance and secondary to tumor volume. During chemotherapy the plasma concentration of estradiol decreased rapidly with the reduction of tumor volume.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3391418     DOI: 10.1016/0090-8258(88)90245-4

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Prevalence of pulmonary embolism at necropsy in patients with cancer.

Authors:  E Svendsen; B Karwinski
Journal:  J Clin Pathol       Date:  1989-08       Impact factor: 3.411

2.  Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells.

Authors:  K M Lau; S C Mok; S M Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

3.  Activation of estrogen receptor α by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells.

Authors:  Sohei Matsumura; Tsuyoshi Ohta; Keiko Yamanouchi; Zhiyang Liu; Takeshi Sudo; Takanobu Kojimahara; Manabu Seino; Megumi Narumi; Seiji Tsutsumi; Toshifumi Takahashi; Kazuhiro Takahashi; Hirohisa Kurachi; Satoru Nagase
Journal:  Cancer Biol Ther       Date:  2016-09-30       Impact factor: 4.742

4.  A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.

Authors:  M J Lind; B M Cantwell; M J Millward; A Robinson; M Proctor; D Simmons; J Carmichael; A L Harris
Journal:  Br J Cancer       Date:  1992-04       Impact factor: 7.640

5.  Ovarian mucinous adenocarcinoma with functioning stroma in postmenopausal women: aromatase and SF-1 expressions.

Authors:  Yuka Hattori; Shizuka Yamada; Makoto Yamamoto; Makoto Orisaka; Tetsuya Mizutani; Yoshio Yoshida
Journal:  J Ovarian Res       Date:  2015-11-14       Impact factor: 4.234

6.  Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors.

Authors:  Jun-Ichi Akahira; Takashi Suzuki; Kiyoshi Ito; Chika Kaneko; Andrew D Darnel; Takuya Moriya; Kunihiro Okamura; Nobuo Yaegashi; Hironobu Sasano
Journal:  Jpn J Cancer Res       Date:  2002-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.